Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Rowland, L. M. Articles by Brooks, W. M. Search for Related Content PubMed Citation Articles by Rowland, L. M. Articles by Brooks, W. M. Neurophysiology Neurotransmitters MRS

Effects of Ketamine on Anterior Cingulate Glutamate Metabolism in Healthy Humans: A 4-T Proton MRS Study

OBJECTIVE: The authors’ goal was to test in humans the hypothesis that N-methyl-D-aspartate receptor (NMDAR) antagonism results in increased cortical glutamate activity, as proposed by the NMDAR hypofunction model of schizophrenia. METHOD: 4-T ¹H proton magnetic resonance spectroscopy (¹H-MRS) was used to acquire in vivo spectra from the bilateral anterior cingulate of 10 healthy subjects while they received a subanesthetic dose of either placebo or ketamine, an NMDAR antagonist. Assessments given before and after ketamine or placebo administration included the Brief Rating Psychiatric Rating Scale, the Scale for the Assessment of Negative Symptoms, the Clinician-Administered Dissociative States Scale, and the Stroop task. RESULTS: As predicted, there was a significant increase in anterior cingulate glutamine, a putative marker of glutamate neurotransmitter release, with ketamine administration. This increase was not related to schizophrenia-like positive or negative symptoms but was marginally related to Stroop performance. CONCLUSIONS: In humans as in animals, an acute hypofunctional NMDAR state is associated with increased glutamatergic activity in the anterior cingulate.

This article has been cited by other articles:

				A. Fornito, M. Yucel, B. Dean, S. J. Wood, and C. Pantelis Anatomical Abnormalities of the Anterior Cingulate Cortex in Schizophrenia: Bridging the Gap Between Neuroimaging and Neuropathology Schizophr Bull, September 1, 2009; 35(5): 973 - 993. [Abstract] [Full Text] [PDF]

				J. THEBERGE, K. E. WILLIAMSON, N. AOYAMA, D. J. DROST, R. MANCHANDA, A. K. MALLA, S. NORTHCOTT, R. S. MENON, R. W. J. NEUFELD, N. RAJAKUMAR, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia The British Journal of Psychiatry, October 1, 2007; 191(4): 325 - 334. [Abstract] [Full Text] [PDF]

				M. L. Spath Continued Controversies: Issues in Mental Health Research and Implications for Nursing Journal of the American Psychiatric Nurses Association, September 1, 2007; 13(4): 221 - 229. [Abstract] [PDF]

				J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]

				C. H. Large Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol, May 1, 2007; 21(3): 283 - 301. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us